arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Absci Corp

ABSI
$9.34 ▼ -1.16 (-11.10%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Absci Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield —
Revenue Growth -46.4% ↗
Op. Margin None
ROIC -13.9% ↗
FCF / Share $-0.18 →
Trailing P/E —
Price / Book 6.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$318.00K
↓ -46.4% —
Net Income Profit after all expenses
$-29.60M
↓ -12.3% —
Operating Margin Operating profit as % of sales
-169.8%
↑ +53.8% —
FCF / Share Free cash flow per share
$-0.18
↓ -1.7% —
Long-Term Debt Long-term obligations
$8.87M
↓ -4.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Financial Health ↓
5
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters